Bristol-Myers Squibb seeks additional approval for Orencia

PRINCETON, N.J. — The Food and Drug Administration has accepted for review a supplemental approval application for an arthritis drug made by Bristol-Myers Squibb, the drug maker said Monday.

Bristol is seeking approval for Orencia (abatacept) injected into the skin as a treatment for adults with moderate to severe rheumatoid arthritis. The drug already is approved for intravenous injection.

The company filed the application in October after a phase-3 trial program of 1,847 patients showed that patients receiving weekly skin injections of the drug showed about the same degree of improvement as those receiving the drug by IV.

Login or Register to post a comment.